JPWO2021182467A1 - - Google Patents
Info
- Publication number
- JPWO2021182467A1 JPWO2021182467A1 JP2022507218A JP2022507218A JPWO2021182467A1 JP WO2021182467 A1 JPWO2021182467 A1 JP WO2021182467A1 JP 2022507218 A JP2022507218 A JP 2022507218A JP 2022507218 A JP2022507218 A JP 2022507218A JP WO2021182467 A1 JPWO2021182467 A1 JP WO2021182467A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glanulating (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024029031A JP2024063111A (ja) | 2020-03-11 | 2024-02-28 | 顆粒及びそれを用いた製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988083P | 2020-03-11 | 2020-03-11 | |
| US62/988,083 | 2020-03-11 | ||
| PCT/JP2021/009284 WO2021182467A1 (ja) | 2020-03-11 | 2021-03-09 | 顆粒及びそれを用いた製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029031A Division JP2024063111A (ja) | 2020-03-11 | 2024-02-28 | 顆粒及びそれを用いた製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021182467A1 true JPWO2021182467A1 (https=) | 2021-09-16 |
| JPWO2021182467A5 JPWO2021182467A5 (https=) | 2022-11-08 |
| JP7487290B2 JP7487290B2 (ja) | 2024-05-20 |
Family
ID=77670617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022507218A Active JP7487290B2 (ja) | 2020-03-11 | 2021-03-09 | 顆粒及びそれを用いた製剤 |
| JP2024029031A Withdrawn JP2024063111A (ja) | 2020-03-11 | 2024-02-28 | 顆粒及びそれを用いた製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029031A Withdrawn JP2024063111A (ja) | 2020-03-11 | 2024-02-28 | 顆粒及びそれを用いた製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230014578A1 (https=) |
| EP (1) | EP4119129A4 (https=) |
| JP (2) | JP7487290B2 (https=) |
| KR (1) | KR20220123689A (https=) |
| CN (1) | CN115209876A (https=) |
| TW (1) | TWI850539B (https=) |
| WO (1) | WO2021182467A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7817300B2 (ja) * | 2023-02-14 | 2026-02-18 | 沢井製薬株式会社 | コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05194193A (ja) * | 1991-11-14 | 1993-08-03 | Dai Ichi Seiyaku Co Ltd | マスクされた粒状物 |
| JPH06116138A (ja) * | 1992-03-12 | 1994-04-26 | Taisho Pharmaceut Co Ltd | 経口製剤用組成物 |
| WO2005117845A1 (ja) * | 2004-06-03 | 2005-12-15 | Taisho Pharmaceutical Co., Ltd. | 経口製剤およびその製造方法 |
| JP2016511223A (ja) * | 2012-12-21 | 2016-04-14 | サノフイ | フェキソフェナジン高含有固形単位およびその製造法 |
| JP2019514993A (ja) * | 2016-05-09 | 2019-06-06 | ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー | 改善された薬物製剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| JP4310605B2 (ja) * | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | 医薬用組成物 |
| KR100913281B1 (ko) * | 2002-02-21 | 2009-08-21 | 오츠카 세이야쿠 가부시키가이샤 | 서방 제제 및 그의 제조 방법 |
| JP5905872B2 (ja) * | 2010-04-07 | 2016-04-20 | ルピン・リミテッド | タペンタドールの制御放出医薬組成物 |
| JP2015054822A (ja) * | 2013-09-10 | 2015-03-23 | ニプロ株式会社 | クロピドグレル含有錠剤およびその製造方法 |
| JP2018083809A (ja) * | 2016-11-16 | 2018-05-31 | 沢井製薬株式会社 | シロドシン含有粒子の製造方法及びシロドシン含有口腔内崩壊錠の製造方法 |
| JP6895779B2 (ja) * | 2017-03-17 | 2021-06-30 | 東和薬品株式会社 | アジルサルタン含有固形医薬組成物 |
-
2021
- 2021-03-09 KR KR1020227026916A patent/KR20220123689A/ko not_active Ceased
- 2021-03-09 WO PCT/JP2021/009284 patent/WO2021182467A1/ja not_active Ceased
- 2021-03-09 EP EP21766854.0A patent/EP4119129A4/en active Pending
- 2021-03-09 JP JP2022507218A patent/JP7487290B2/ja active Active
- 2021-03-09 CN CN202180017989.5A patent/CN115209876A/zh active Pending
- 2021-03-10 TW TW110108516A patent/TWI850539B/zh active
-
2022
- 2022-09-12 US US17/942,333 patent/US20230014578A1/en active Pending
-
2024
- 2024-02-28 JP JP2024029031A patent/JP2024063111A/ja not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05194193A (ja) * | 1991-11-14 | 1993-08-03 | Dai Ichi Seiyaku Co Ltd | マスクされた粒状物 |
| JPH06116138A (ja) * | 1992-03-12 | 1994-04-26 | Taisho Pharmaceut Co Ltd | 経口製剤用組成物 |
| WO2005117845A1 (ja) * | 2004-06-03 | 2005-12-15 | Taisho Pharmaceutical Co., Ltd. | 経口製剤およびその製造方法 |
| JP2016511223A (ja) * | 2012-12-21 | 2016-04-14 | サノフイ | フェキソフェナジン高含有固形単位およびその製造法 |
| JP2019514993A (ja) * | 2016-05-09 | 2019-06-06 | ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー | 改善された薬物製剤 |
Non-Patent Citations (1)
| Title |
|---|
| PAWAR ASHOK HARSHAL ET AL.: "Development and Evaluation of Taste Masked Granular Formulation of Satranidazole by Melt Granulation", JOURNAL OF PHARMACEUTICS, vol. Volume 2014, Article ID 789676, JPN6021014774, 2014, pages 1 - 7, ISSN: 0005206596 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4119129A1 (en) | 2023-01-18 |
| WO2021182467A1 (ja) | 2021-09-16 |
| EP4119129A4 (en) | 2024-01-24 |
| TWI850539B (zh) | 2024-08-01 |
| KR20220123689A (ko) | 2022-09-08 |
| JP2024063111A (ja) | 2024-05-10 |
| CN115209876A (zh) | 2022-10-18 |
| JP7487290B2 (ja) | 2024-05-20 |
| TW202200118A (zh) | 2022-01-01 |
| US20230014578A1 (en) | 2023-01-19 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220909 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220909 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231005 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240228 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240319 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240423 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240508 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7487290 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |